S-J Park1, K-W Jo1, B Yoo2, C-K Lee2, Y-G Kim2, S-K Yang3, J-S Byeon3, K-J Kim3, B D Ye3, S-H Park3, T S Shim1. 1. Department of Pulmonary and Critical Care Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea. 2. Department of Rheumatology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea. 3. Department of Gastroenterology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea.
Abstract
SETTING: A tertiary referral centre in South Korea. OBJECTIVE: To compare the completion rates and adverse drug reactions of three latent tuberculous infection (LTBI) treatment regimens for patients receiving anti-tumour necrosis factor (anti-TNF) therapy. DESIGN: A total of 408 patients were diagnosed with LTBI before receiving anti-TNF therapy between December 2004 and December 2013. Nine months of isoniazid (9H), 4 months of rifampicin (4H) or 3 months of isoniazid/rifampicin (3HR) were prescribed. The results were analysed retrospectively. RESULTS: The mean age of the 408 study subjects was 44 years; 258 (63.2%) were male. The 9H, 4R and 3HR treatment regimens were given to respectively 61 (15.0%), 139 (34.1%) and 208 (51.0%) patients. A total of 362 (88.7%) patients completed the treatment. The treatment completion rate was highest in patients receiving 3HR (94.2%). Of the 408 patients, 54 (13.2%) had one or more adverse drug reactions; their frequency was similar in the three groups. CONCLUSIONS: In patients receiving anti-TNF therapy, 3HR seems to be the most acceptable treatment regimen for LTBI, given its high completion rate and acceptable rate of adverse drug reactions.
SETTING: A tertiary referral centre in South Korea. OBJECTIVE: To compare the completion rates and adverse drug reactions of three latent tuberculous infection (LTBI) treatment regimens for patients receiving anti-tumour necrosis factor (anti-TNF) therapy. DESIGN: A total of 408 patients were diagnosed with LTBI before receiving anti-TNF therapy between December 2004 and December 2013. Nine months of isoniazid (9H), 4 months of rifampicin (4H) or 3 months of isoniazid/rifampicin (3HR) were prescribed. The results were analysed retrospectively. RESULTS: The mean age of the 408 study subjects was 44 years; 258 (63.2%) were male. The 9H, 4R and 3HR treatment regimens were given to respectively 61 (15.0%), 139 (34.1%) and 208 (51.0%) patients. A total of 362 (88.7%) patients completed the treatment. The treatment completion rate was highest in patients receiving 3HR (94.2%). Of the 408 patients, 54 (13.2%) had one or more adverse drug reactions; their frequency was similar in the three groups. CONCLUSIONS: In patients receiving anti-TNF therapy, 3HR seems to be the most acceptable treatment regimen for LTBI, given its high completion rate and acceptable rate of adverse drug reactions.
Authors: Eun Hye Lee; Young Ae Kang; Ah Young Leem; Moo Suk Park; Young Sam Kim; Se Kyu Kim; Joon Chang; Song Yee Kim Journal: Sci Rep Date: 2017-07-25 Impact factor: 4.379
Authors: Dae Hyun Jeong; Jieun Kang; Young Ju Jung; Bin Yoo; Chang-Keun Lee; Yong-Gil Kim; Seokchan Hong; Tae Sun Shim; Kyung-Wook Jo Journal: PLoS One Date: 2018-07-05 Impact factor: 3.240
Authors: Michael Scolarici; Ken Dekitani; Ling Chen; Marcia Sokol-Anderson; Daniel F Hoft; Soumya Chatterjee Journal: PLoS One Date: 2018-11-15 Impact factor: 3.240
Authors: Beong Ki Kim; Hee Jin Kim; Ho Jin Kim; Jae Hyung Cha; Jin Beom Lee; Jeonghe Jeon; Chi Young Kim; Young Kim; Je Hyeong Kim; Chol Shin; Seung Heon Lee Journal: Tuberc Respir Dis (Seoul) Date: 2019-05-31